ナイジェリアの HIV 陽性女性の子宮頸がん制御へのアクセスを増やすための地域、家庭ベースの教育、スクリーニング サービス戦略
ナイジェリアの HIV 陽性女性の子宮頸がん制御へのアクセスを増やすためのコミュニティ、在宅教育、スクリーニング サービス (CHESS) 戦略
The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims:
- Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population.
- Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity.
- Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.
調査の概要
詳細な説明
Despite the increased risk of cervical cancer (CC) among women living with HIV (WLWH), access to CC screening in Nigeria remains limited. While advances in prevention programs and antiretroviral therapy have reduced other AIDS-associated malignancies, CC risk in WLWH persists. This study aims to leverage Nigeria's existing HIV treatment infrastructure to integrate home-based CC (HCC) screening for WLWH.
The approach involves adapting the MoMent (MOther MENTor) peer-based HIV support program to include HCC screening and evaluating its implementation and sustainability using the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks. The study has three key aims:
- Adapting the MoMent program to promote home-based HPV screening and follow-up treatment through stakeholder deliberation.
- Implementing and assessing the program's reach, effectiveness, adoption, and fidelity with a sample of 1,500 WLWH.
- Conducting a post-implementation evaluation to identify barriers and enablers for program maintenance and scalability.
Stakeholder input, including perspectives from WLWH, peer counselors, clinical managers, and policymakers, will guide the program's design and execution. By integrating stakeholder insights and addressing systemic challenges, the study aims to advance CC control in Nigeria and provide a scalable model for implementing cancer control strategies for people living with HIV in low- and middle-income countries globally.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
-
Abuja、ナイジェリア
- APIN Health Initiatives
-
Ibadan、ナイジェリア
- University of Ibadan
-
Lagos、ナイジェリア
- Nigeria Institute of Medical Research (NIMR
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Aim 1: The stakeholder deliberation conferences will include stakeholders from the following groups:
- State and National Policymakers
- Organizational-clinical managers
- Mentor mothers
- Women living with HIV (WLWH) Since this is a socio-behavioral component, pregnant individuals may partake. All individuals who take part in this portion of the study will be above 18 and capable of providing informed consent.
Aim 2: This study will only include WLWH aged 25-50. Pregnant individuals will not be included due to the potential for treatment of precancerous lesions. All individuals who partake in the study will be older than 18 and capable of providing informed consent.
説明
Inclusion Criteria:
- Patients must be able to perform vaginal self-collection as well as give informed consent
Exclusion Criteria:
- Male gender
- Age <25 or >50
- Unknown or negative HIV status
- Pregnancy
- Hysterectomy
- Inability to give informed consent Inability/refusal to perform vaginal self-collection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Women living with HIV
During the screening process:
WLWH testing positive for HrHPV 16/18/45 via self-collection will be notified by a Mentor Mother, who, along with Nigerian clinical staff, will assist in scheduling VIA. Treatment follows the standard of care protocol. |
The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
他の名前:
A cervical cancer screening tool. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Program Reach
時間枠:Baseline, Month 6, Month 18
|
Reach evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or reoccurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Effectiveness of the Program
時間枠:Baseline, Month 6, Month 18
|
Effectiveness evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or recurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Adoption of the program
時間枠:Baseline, Month 6, Month 18
|
Adoption will be measured through the proportions of MMs who complete training and WLWH who return self-collected (SC) samples |
Baseline, Month 6, Month 18
|
|
Fidelity of the program
時間枠:Baseline, Month 6, Month 18
|
Will be measured by peer leaders' monitoring of practices, as well as measuring system barriers and added MoMent program costs per completed home screening |
Baseline, Month 6, Month 18
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Lisa Flowers, MD, MPH、Emory University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY00004817
- U01CA275113 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data shared:
De-identified sociodemographic data (e.g., race/ethnicity, age). Health behavior and health care utilization data from medical records. Cervical pathology results, HPV testing data, laboratory tests (e.g., CD4 and viral load), prescribed HIV medications, and adherence data.
Qualitative data from in-depth interviews and focus group discussions, coded and anonymized.
IPD 共有時間枠
Start Date: After primary analyses have been completed and results are published (expected within 12 months of study completion).
End Date: Indefinitely, contingent on adherence to data-sharing agreements
IPD 共有アクセス基準
Researchers will submit a Data Analysis Request Form, detailing their proposed analysis, purpose, and data needed.
Data access will be granted following review and approval. Approved users will sign a Data Use and Confidentiality Agreement. Anonymized data will be shared securely via a designated data repository or encrypted file transfer.
Researchers must commit to using the data for specified purposes, implementing secure data storage, and destroying or returning the data after analyses are completed.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。